HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Nestle Health Science

https://www.nestlehealthscience.com/

Latest From Nestle Health Science

Finance Watch: Two New VC Funds Raise $755m To Fund Innovation

Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.

Financing StartUps and SMEs

Stockwatch: Winlevi And Aimmune Excitement Will Be Short-Lived

Apparently positive news for two unglamorous indications – acne and allergy – should be balanced against restrictive reimbursement and market fragmentation.

Stockwatch M & A

Stockwatch: The Fall, Rise And Challenges Of Seres' Microbiome Therapy

The public biotech’s first foray into the microbiome started well, but a clinical trial failure followed by a success has now left Seres with both regulatory and commercial issues.

Companies Regulation

Nestle Pairs Nutrition Science Business With Pharma Firm Making Peanut Allergy Treatment

Nestle agrees to acquire Aimmune Therapeutics, maker of a drug indicated to reduce the severity of children’s allergic reactions to peanuts. It anticipates options to innovate in its consumer health children’s allergy business.

Dietary Supplements Consumer
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Prometheus Laboratories, Inc., Nestle S.A.
UsernamePublicRestriction

Register